Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced significant data presentations at the ASGCT 24th Annual Meeting, scheduled for May 11-14, 2021. Key highlights include:

• First reporting on novel capsid technology.
• Oral presentations on RNA-driven AAV capsid evolution, anti-Tau antibody efficacy in mouse models, and capsid separation techniques.
• Poster presentations on AAV gene therapy for chronic pain and AAV vector ultrafiltration.
• Industry symposium on advancing AAV gene therapy for CNS diseases.

For more information, visit Voyager's website.

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 24^th Annual Meeting taking place virtually on May 11-14, 2021. Oral presentations include the first reporting on the company’s novel capsid technology.

The ASGCT abstracts are now available at https://www.asgct.org/, with full meeting content available for 30 days for registered attendees.

Details for the oral presentations are as follows:

Title: RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System
Session: Novel AAV Capsids for Brain, Eye and Muscle Tissues
Date/time: May 11, 2021, 5:45-6:00 p.m. ET
Abstract number: 51

Title: Efficacy of a Vectorized Anti-Tau Antibody Using Systemic Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mouse Models of Tauopathies
Session: Preclinical Gene Therapy for Neurologic Disorders II
Date/time: May 12, 2021, 7:00-7:15 p.m. ET
Abstract number: 105

Title: Separation of Empty Capsids from Full Capsids for AAV Gene Therapy Using a Flow Through and Step Elution Approach
Session: Lentivral Vector Manufacturing
Date/time: May 14, 2021, 1:45-2:00 p.m. ET
Abstract number: 228

Details for the poster presentations are as follows:

Title: Developing an AAV Delivered Gene Therapy for Chronic Pain through Inhibition of NaV1.7 Expression
Session: Neurologic Diseases
Date/time: May 11, 2021, 8:00-10:00 a.m. ET
Abstract number: 548

Title: Ultrafiltration Behavior of Adeno-Associated Viral Vectors (AAVs) in Gene Therapy: Process Considerations for High Concentration UF/DF
Session: Vector Product Engineering, Development or Manufacturing
Date/time: May 11, 2021, 8:00-10:00 a.m. ET
Abstract number: 835

Title: Expression of AAV Rep78 and Rep52 from Distal Baculovirus loci for Production of Gene Therapy Vectors: Proof-of-Concept and Initial Optimization
Session: Vector Product Engineering, Development or Manufacturing
Date/time: May 11, 2021, 8:00-10:00 a.m. ET
Abstract number: 847

Details for the digital presentations are as follows:

Title: Increasing Baculovirus/Sf9 Platform Productivity by Developing a Fed-Batch Production Process
Date: May 11-14, 2021
Abstract number: 845

Title: Characterizing the Impact of Shear on SF9 Cells Used in the Baculovirus Expression System for Recombinant AAV Gene Therapy Vector Production
Date: May 11-14, 2021
Abstract number: 856

Voyager is also presenting an Industry Sponsored Symposium titled "Advancing AAV Gene Therapy for CNS Disease," scheduled for Wednesday, May 12, 2021 at 2:00 p.m. ET. The symposium will feature the following speakers and presentations:

David Schaffer, Ph.D.: “Building a Better AAV Capsid for CNS Gene Therapies”

Guangping Gao, Ph.D.: “Optimizing the Transgene for AAV CNS Gene Therapies”

Mark Richardson, M.D., Ph.D.: “Evolving Approaches to Direct Delivery of AAV CNS Gene Therapies”

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information on Voyager Therapeutics, please visit the company’s website at www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Investors:
investors@voyagertherapeutics.com 

Media:
Sheryl Seapy
W2Opure
949-903-4750
sseapy@purecommunications.com

FAQ

What is Voyager Therapeutics presenting at the ASGCT 2021?

Voyager Therapeutics is presenting multiple data highlights at the ASGCT 2021, focusing on novel capsid technology and gene therapy for severe neurological diseases.

When are Voyager's presentations scheduled at ASGCT 2021?

Voyager's presentations are scheduled between May 11-14, 2021, with key oral sessions on May 11 and 12.

What topics will Voyager discuss during the oral presentations?

The oral presentations will cover RNA-driven AAV capsid libraries, anti-Tau antibody efficacy in mice, and separation techniques for gene therapy.

What sessions are included in Voyager's poster presentations at ASGCT 2021?

The poster presentations include gene therapy for chronic pain, ultrafiltration behavior of AAV vectors, and AAV Rep78 and Rep52 expression optimization.

What is the date and time for Voyager's industry symposium at ASGCT 2021?

The industry-sponsored symposium titled 'Advancing AAV Gene Therapy for CNS Disease' is scheduled for May 12, 2021, at 2:00 p.m. ET.